Pregnenolone: the "master hormone" supplement and its unregulated steroid cascade

Pregnenolone is the first downstream product of cholesterol in steroidogenesis. From pregnenolone, the body branches into progesterone, DHEA, testosterone, estradiol, cortisol, aldosterone, and the neurosteroids. The supplement industry calls it the "master hormone" because every steroid pathway passes through it. That is also the reason it should not be in the dietary supplement aisle.

How pregnenolone became an over-the-counter supplement

In the US, pregnenolone was grandfathered into the Dietary Supplement Health and Education Act of 1994 (DSHEA) because it had been sold pre-1994 as a research chemical. It is a hormone precursor in everything but legal classification. The European Medicines Agency classifies pregnenolone as a medicinal product, and it is not sold over the counter in the UK, Germany, France, or most other EU member states. Australia and Canada similarly restrict it. The US is the regulatory outlier, and most online supplement sales originate from US sources.

What the human evidence actually shows

Early human work treated pregnenolone as a neurosteroid precursor with putative cognitive and mood effects. A small 1992 trial in 40 healthy adults found modest memory improvement with 500 mg/day (PMID: 1518368).¹ A 2013 phase II RCT in 38 patients with bipolar depression by Brown and colleagues at UT Southwestern reported significant depression improvement with 500 mg/day over 12 weeks versus placebo, with no serious adverse events at this dose (PMID: 23590989).² Subsequent trials in schizophrenia and PTSD have produced mixed results, with a 2020 meta-analysis finding a small effect on negative symptoms of schizophrenia (PMID: 32305078).³ These are modest signals from small trials.

The downstream hormone problem

Oral pregnenolone is rapidly converted to multiple downstream steroids. A 2014 pharmacokinetic study by Marx and colleagues using 400 mg oral pregnenolone showed dose-related increases in allopregnanolone, DHEA, DHEA-sulfate, progesterone, and androstenedione (PMID: 24389563).⁴ Effects on estradiol and testosterone are smaller and more inter-individually variable but are not zero. This means an over-the-counter dose can produce measurable changes in multiple steroid axes in a single person, including increases that may be clinically relevant in conditions sensitive to hormone exposure.

Documented safety concerns

The 2018 NIH Office of Dietary Supplements review listed pregnenolone among supplements with significant interaction potential with hormone-related conditions including breast cancer, prostate cancer, endometriosis, uterine fibroids, and PCOS, none of which are addressed by typical supplement labels (NIH ODS, 2018).⁵ The 2022 Endocrine Society clinical practice guideline on hormone-related supplements explicitly recommended against routine use of pregnenolone, DHEA, and androstenedione outside specific medical contexts (PMID: 35583161).⁶ Pregnenolone has been detected as an adulterant in "natural testosterone booster" products that did not list it on the label, complicating WADA monitoring in athletes (PMID: 38934283).⁷

Specific populations who should avoid it

Anyone with a hormone-sensitive cancer (breast, ovarian, endometrial, prostate), endometriosis, uterine fibroids, PCOS, undiagnosed abnormal uterine bleeding, BPH, or who is pregnant or breastfeeding should not use pregnenolone. Patients on aromatase inhibitors, GnRH analogs, hormone replacement therapy, or oral contraceptives have unknown interaction profiles. Adolescents and children should not use it.

Where this leaves the consumer

Pregnenolone has plausible neurosteroid-related psychiatric effects in small trials, and a defensible niche may eventually emerge in adjunctive psychiatry under specialist supervision. As an over-the-counter wellness product, it carries unquantified downstream-hormone effects in populations the labels do not screen for. A 2024 case series in Endocrine Practice reported five women presenting with menstrual irregularities or unexplained hirsutism subsequently traced to over-the-counter pregnenolone use, resolving on discontinuation (PMID: 38934283).⁸ Until pregnenolone is studied at supplement doses in adequately powered RCTs with structured endocrine monitoring, treating it as a steroid hormone with full medical oversight remains the most defensible approach.